---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-25-000188"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2025-09-11T23:59:59+00:00"
generated_at: "2026-05-17T06:51:49.201986+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Emergent gets $56M ACAM2000 contract modification; 2025 sales projected >$120M

## Summary
- Contract Modification No. 14 valued at $56M; deliveries to U.S. government by Dec 31, 2025.
- Total 2025 projected sales for ACAM2000 and ancillary products exceed $120M from diverse customer base.
- ACAM2000 is FDA-approved for smallpox (2007) and mpox (Aug 2024); also licensed in Canada, Australia, Singapore.
- Modification exercises Option Year 6 under existing 10-year ASPR contract (75A50119C00071).

## SEC filing metadata
- accession: 0001367644-25-000188
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2025-09-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000188/0001367644-25-000188-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000188/ebs-20250905.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-25-000188
- JSON: https://secwatch.observer/filing/0001367644-25-000188.json
- Plain text: https://secwatch.observer/filing/0001367644-25-000188.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.